Early Diagnosis of Dementia
Karen S. Santacruz
Until recently, the most significant issue facing a family physician regarding the diagnosis and treatment of dementia was ruling out delirium and potentially treatable etiologies. However, as more treatment options become available, it will become increasingly important to diagnose dementia early. Dementia may be suspected if memory deficits are exhibited during the medical history and physical examination. Information from the patient’s family members, friends and caregivers may also point to signs of dementia. Distinguishing among age-related cognitive decline, mild cognitive impairment and Alzheimer’s disease may be difficult and requires evaluation of cognitive and functional status. Careful medical evaluation to exclude treatable causes of cognitive impairment is important. Patients with early dementia may benefit from formal neuropsychologic testing to aid in medical and social decision-making. Follow-up by the patient’s family physician is appropriate in most patients. However, a subspecialist may be helpful in the diagnosis and management of patients with dementia with an unusual presentation or following an atypical course. (Am Fam Physician 2001; 63:703-13,717-8.)
The prevalence of dementia is expected to increase dramatically in future years as life expectancy continues to increase and the baby-boomer population ages. The cumulative incidence of Alzheimer’s disease has been estimated to be as high as 4.7 percent by age 70, 18.2 percent by age 80 and 49.6 percent by age 90.(1) Proposed risk factors for dementia include a family history of dementia, previous head injury, lower educational level and female sex.(2) Alzheimer’s disease is the most common cause of dementia; many of the remaining cases of dementia are caused by vascular disease and Lewy body disease. Vascular disease and Lewy body disease often occur in combination with Alzheimer’s disease.(3,4)
A practical approach to the diagnosis of dementia begins with the clinical recognition of a progressive decline in memory, a decrease in the patient’s ability to perform activities of daily living, psychiatric problems, personality changes and problem behaviors (Table 1).(5) While the clinical presentation of dementia may vary, depending on the etiology, the diagnostic features are constant. They are well described in the Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) and summarized in Table 2.(6)
The early diagnosis of dementia requires careful questioning to elicit clues to the presence of functional and cognitive impairment (Table 3).(5) Interviewing friends as well as family members is helpful, because family members may have adopted coping strategies to help the patient with dementia, which sometimes conceal the patient’s impairment, making early diagnosis difficult. For example, a caregiver may take on additional responsibilities such as shopping and financial management, possibly masking the patient’s level of impairment.
During the medical history-taking, questions should be asked about forgetfulness and orientation. Inquiries should also be made regarding activities of daily living, including instrumental activities such as everyday problem solving and handling of business and financial affairs. Independent functioning in community affairs, such as job responsibilities, shopping and participation in volunteer and social groups, should be assessed. Evidence of problems with home activities, hobbies and personal care should also be sought. In the early stages of dementia, the patient may show restricted interest in hobbies and other activities, and may require prompting to maintain personal hygiene.(7)
A variety of rating scales are available for evaluating cognitive function. Their use may or may not be required in the evaluation of early dementia.
PHYSICAL EXAMINATION AND COGNITIVE TESTING
The findings of the physical examination may suggest an etiology for dementia. For example, dementia resulting from vascular disease may be accompanied by focal neurologic findings.
Physical examination should include assessment of cognitive domains, including speech (aphasia), motor memory (apraxia), sensory recognition (agnosia) and complex behavior sequencing (executive functioning). Aphasia may be detected by asking the patient to name body parts or objects in the room. Frequent use of vague terms such as “thing” and “it” may also signify deterioration of language function. An example of a test for apraxia is to ask the patient to pantomime the use of a common object such as a hammer or a toothbrush. Agnosia can be evaluated by first asking the patient to close his or her eyes and then placing an object, such as a key or a coin, in the patient’s hand and asking the patient to identify it without looking at it. Inability to recognize a common object despite normal sensory function signifies agnosia.
Asking the patient to perform a series of simple tasks is a way to evaluate executive functioning. For example, the patient can be asked to put a piece of paper in his or her right hand, fold it in half and put it on the floor. This task would be difficult for a patient with impairment in the ability to plan, initiate, sequence and monitor complex behavior. Asking the patient to perform serial subtraction of 7s (backward from 100 to 65), to spell the word “world” backward and to produce verbal word lists, such as names of animals or items in a grocery store, are other ways to test executive functioning and abstract thinking.
Although the Mini-Mental State Examination (MMSE) is not diagnostic of dementia and does not distinguish well between various confusional states,(8) it is useful for assessing cognitive function and documenting subsequent decline (Figure 1). Because judgment and insight are not tested by the MMSE, many clinicians ask additional questions to assess these aspects of cognition. Judgment and insight can be assessed, for example, by asking the patient, “What would you do if you were in a crowded building and smelled smoke?”
When conversational skills are well preserved, an early decline in memory may be difficult to detect, especially during a short, focused office visit. The MMSE can detect cognitive impairment by evaluating orientation, attention, recall, language and ability to follow commands. A score higher than 23 is generally considered normal, although performance varies with the patient’s age and education (Table 4).(9)
Figure 2 summarizes an approach to the early diagnosis of dementia. If dementia is suspected, a medication review and assessment for chronic disease processes are warranted. If no improvement occurs after appropriate measures are taken to eliminate unnecessary medications and optimize treatment of chronic diseases, physical examination and laboratory tests are recommended to rule out specific treatable causes of dementia. Hearing or vision deficits, hypothyroidism, vitamin B12 deficiency and depression are among the disorders that can cause symptoms of dementia. Such disorders are relatively easy to detect and should be excluded by appropriate laboratory tests, physical examination and psychologic tests. Electrocardiography and chest radiography can sometimes be useful to rule out treatable systemic diseases, although their necessity should be guided by the history and physical examination.
Table 5 lists laboratory tests to consider in the evaluation of dementia. Tests recommended for the diagnostic work-up of dementia include a complete blood cell count (to exclude anemia and infection), urinalysis (to exclude infection), serum electrolyte, glucose and calcium levels, blood urea nitrogen, serum creatinine level and liver function tests (to investigate metabolic disease).(10) Syphilis serology, erythrocyte sedimentation rate, serum folate level, human immunodeficiency virus (HIV) status, urine check for heavy metals and toxicology screening may be indicated in a minority of cases (Table 6).(5)
Lumbar puncture is usually not necessary except when the onset of dementia occurs before 55 years of age or when a specific condition such as infection, syphilis or vasculitis is suspected.(10) However, in at least one prospective study it was found that cerebrospinal fluid analysis for the 42 amino acid form of b-amyloid may be suggestive of Alzheimer’s dementia, although not diagnostic.(11) Further studies into the existence of biomarkers for the diagnosis of early Alzheimer’s disease are ongoing.
The utility of computed tomography or magnetic resonance imaging to rule out vascular disease, tumor, subdural hematoma or normal-pressure hydrocephalus remains controversial. Radiologic imaging of the central nervous system is probably not necessary in patients presenting with dementia, unless localizing neurologic signs or symptoms are noted. Clearly, it is important to search for a reversible cause of dementia. However, in one meta-analysis it was revealed that fewer than 11 percent of patients with cognitive decline had partially or fully reversible disease.(12)
DSM-IV criteria for the diagnosis of dementia require the presence of multiple cognitive deficits in addition to memory impairment(6) (Table 1). Early in the disease, memory impairment may be the only clinical finding, and this single finding would not meet the diagnostic criteria for dementia. In order to fulfill DSM-IV criteria, cognitive impairment must be of the degree that social or occupational function is reduced, with the functional impairment representing a decrease in the patient’s normal ability.
AGE-RELATED COGNITIVE DECLINE AND MILD COGNITIVE DISORDER
Age-related cognitive decline is characterized by memory loss without other cognitive problems (the DSM-IV criteria are described in Table 2). If memory deficit is present but the other diagnostic criteria for dementia are not, a diagnosis other than dementia should be considered.(6) A disorder similar to age-related cognitive decline is described as “mild cognitive disorder” in the World Health Organizations ICD-10 classification (International Statistical Classification of Diseases, 10th rev.).(13)
The diagnosis of mild cognitive disorder can be made if the cognitive decline is temporally related to cerebral or systemic disease. Otherwise, the diagnosis of age-related cognitive decline should be considered. According to the DSM-IV, age-related cognitive decline represents cognitive changes that are within normal limits given the person’s age. Age-associated cognitive decline is characterized by a decline in only one of the five broad neuropsychologic domains associated with dementia: memory and learning; attention and concentration; thinking; language; and visuospatial functioning.(14) According to the International Psychogeriatric Association,(14) additional criteria should be met to make a diagnosis of age-related cognitive decline. These criteria include the report of cognitive decline from a reliable source, a gradual onset of at least six months’ duration and a score of more than one standard deviation below the norm on standardized neuropsychologic testing such as the MMSE.
MILD COGNITIVE IMPAIRMENT
The diagnosis of mild cognitive impairment is difficult and controversial. The term “mild cognitive impairment” has been coined to describe a condition that may or may not eventually lead to dementia.(13) One study showed that patients with mild cognitive impairment had a more rapid decline in cognitive function than control patients, but a less rapid decline than patients with mild Alzheimer’s disease.(15)
The definitions of and the distinctions between mild cognitive disorder, age-associated cognitive decline and mild cognitive impairment are controversial. Referral for more extensive neuropsychologic testing, with follow-up intervals of six to nine months, is warranted in patients with mild or borderline cognitive deficits.(16)
The decision to refer the patient with recently diagnosed dementia to a subspecialist is influenced by both practical and medical considerations. Many family physicians choose to follow their patients with dementia even when clinical features are atypical or suggestive of less common etiologies for the dementia.
However, a neurologist or psychiatrist can sometimes assist in the diagnosis and care of patients with less common dementias, including Pick’s disease, dementia of frontal lobe type, dementia with Lewy bodies, progressive supranuclear palsy, multiple-systems atrophy and normal-pressure hydrocephalus. Consensus criteria have been established for the diagnoses of dementia with Lewy bodies and vascular, or multi-infarct, dementia (Table 7).(17,19) Symptoms that may be helpful in identifying the less common causes of dementia include significant personality changes, extrapyramidal signs, rapid progression, gaze palsy, parasympathetic abnormalities, cerebellar signs, early urinary incontinence and gait abnormalities. Other reasons for referral to a neurologist or psychiatrist include rapidly progressive dementia, dementia in a young patient or the presence of psychiatric comorbidities or severe behavior disturbances.
In a nonresearch setting, neuropsychologic testing is not considered necessary if the diagnosis of dementia can be made using standard criteria. In general, neuropsychologic testing is indicated when patients with abnormal findings on the mental state examination show normal physical functioning and when the index of suspicion is clinically high but screening tests are normal.(16) Neuropsychologic tests evaluate a wide variety of intellectual domains, including the level of arousal, attention and orientation, recent and remote memory, language, praxis, visuospatial function, calculations and judgment. Although there are published norms for most of the commonly used standardized tests, the tests are not always definitive. Serial examination may be necessary. Neuropsychologic tests may also be useful in determining competency for legal purposes, in distinguishing dementia from depression and in helping the patient make important decisions regarding jobs and finances.
Management and Treatment
Early diagnosis and intervention allow the patient to compensate for the disability, minimize disease-related and medication complications, improve quality of life and optimize the use of resources. While new experimental cholinergic drugs for the treatment of Alzheimer’s disease are introduced periodically, tacrine (Cognex) and donepezil (Aricept) are the only cholinesterase inhibitors currently labeled for the symptomatic treatment of Alzheimer’s disease. Acetylcholinesterase inhibitors act by delaying neurotransmitter degradation, thereby enhancing cortical cholinergic activity.
Clinical trials in patients with mild to moderate dementia suggest that symptomatic improvement is possible.(20,21) Cholinergic side effects, such as nausea, vomiting and diarrhea, are usually transient but may be intolerable to some patients. Monitoring of serum transaminase levels is recommended with use of tacrine because of potential hepatotoxicity. Experimental treatment options, some with potentially fewer side effects than those associated with currently available agents, may soon be available for the treatment of Alzheimer’s disease.
The primary management strategy for progressive dementia is to preserve function and independence, and to maintain quality of life for as long as possible. Frequent (every three to six months) clinic visits may be indicated to achieve these goals by maximizing the patient’s general health and interacting with caregivers to optimize the patient’s social environment. Nonpharmacologic interventions, including measures to ensure safety at home and long-term decisions regarding finances, a living will and nursing home placement, are often important considerations.
The management of vascular dementia consists of controlling risk factors such as hypertension and smoking. The use of anticoagulants is indicated in many of these patients. Because of its safety, aspirin is the most commonly used agent. Use of warfarin (Coumadin) may also be considered in a limited number of patients, such as those without a significant risk of falling but with a definite history of stroke.
The treatment of dementia with Lewy bodies has not been well studied. However, it is important to note that parkinsonian features in these patients rarely respond to dopaminergic drugs, and that adverse responses to neuroleptic agents may occur.(22)
Physicians and patients can obtain information about potential experimental treatment options and ongoing clinical trials at the Alzheimer’s Disease Education and Referral (ADEAR) Center Web site (www.alzheimers. org) or through an Alzheimer’s disease information specialist at ADEAR (800-438-4380). The ADEAR Center is a service of the National Institute on Aging (NIA).
Although no method of curing or arresting Alzheimer’s disease is currently available, early diagnosis is important for several reasons. The most compelling reason is that early diagnosis allows the patient and family to plan for the future and identify outside sources of assistance. Moreover, as potentially useful and proven treatments become available, early diagnosis of dementia will become increasingly important. Although screening all elderly patients for dementia is not warranted,(23) being alert for cognitive and functional decline is a prudent way of recognizing dementia in its early stage.
(1.) Hebert LE, Scherr PA, Beckett LA, Albert MS, Pilgrim DM, Chown MJ, et al. Age-specific incidence of Alzheimer’s disease in a community population. JAMA 1995;273:1354-9.
(2.) Larson EB, Kukull WA, Katzman RL. Cognitive impairment: dementia and Alzheimer’s disease. Annu Rev Public Health 1992;13:431-49.
(3.) Bachman DL, Wolf PA, Linn R, Knoefel JE, Cobb J, Belanger A, et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992;42:115-9.
(4.) Collerton D, Davies C, Thompson P. Lewy body dementia in clinical practice. In: Perry RH, McKeith IG, Perry EK, eds. Dementia with Lewy bodies: clinical, pathological, and treatment issues. New York: Cambridge University Press, 1996:171-86.
(5.) Rabins PV, Lyketsos CG, Steele CD. Practical dementia care. New York: Oxford University Press, 1999.
(6.) American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association, 1994:123-63,684.
(7.) Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993; 43:2412-4.
(8.) Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
(9.) Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational levels. JAMA 1993;18:2386-91.
(10.) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter for diagnosis and evaluation of dementia. Neurology 1994;44:2203-6.
(11.) Andreason N, Hesse C, Davidson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer’s disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999;56:673-80.
(12.) Clarfield AM. The reversible dementias: do they reverse? Ann Intern Med 1988;109:476-86.
(13.) World Health Organization. The ICD-10 classification of mental and behavioral disorders. Geneva: World Health Organization, 1992:64-5.
(14.) Levy R. Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr 1994;6:63-8 [Published erratum in Int Psychogeriatr 1994;6:133].
(15.) Peterson RC, Smith GE, Waring SC, Ivnik RJ, Tangelos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome Arch Neurol 1999;56:303-8 [Published erratum in Arch Neurol 1999;56:760].
(16.) Daly MP. Diagnosis and management of Alzheimer Disease. J Am Board Fam Pract 1999;12:375-85.
(17.) McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
(18.) Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic Treatment Centers. Neurology 1992;42:473-80.
(19.) Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-8.
(20.) Rogers SL, Farlow MR, Doody RS,Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998;50:136-45.
(21.) Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 1997;336:1216-22.
(22.) McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673-8.
(23.) U.S. Preventive Services Task Force. Guide to clinical preventive services. 2d ed. Baltimore: Williams & Wilkins, 1996.
KAREN S. SANTACRUZ, M.D., is an assistant professor in the departments of pathology and neurology at the University of Kansas School of Medicine, Kansas City. She completed a residency at the University of California, Irvine, Medical Center, where she trained in anatomic pathology and neuropathology. She developed an interest in dementia through her interaction with the Alzheimer’s Disease Research Center at the University of California, Irvine.
DANIEL SWAGERTY, M.D., M.P.H., is an assistant professor in the departments of family medicine and internal medicine in the University of Kansas School of Medicine. He is also associate director of the Center on Aging at the University of Kansas. Dr. Swagerty completed medical school, a family practice residency and a geriatric medicine fellowship at the University of Kansas School of Medicine. He also completed a master’s degree in public health at the University of Kansas School of Medicine.
Address correspondence to Karen S. SantaCruz, M.D., Department of Pathology, University of Kansas School of Medicine, 3901 Rainbow Blvd., Kansas City, KS 66160-7410. Reprints are not available from the authors.
COPYRIGHT 2001 American Academy of Family Physicians
COPYRIGHT 2001 Gale Group